Immatics Q3 2026 net loss widens 50% to EUR 76.02 million
IMTX•Immatics’ third-quarter 2026 net loss widened 50% year over year to EUR 76.02 million, while revenue rose 33% to EUR 6.92 million. The company reported EUR 472.3 million in cash and other financial assets and projected cash reach into Q4 2028.
1. Quarterly results
Immatics’ third-quarter 2026 net loss widened 50% year over year to EUR 76.02 million, and revenue rose 33% to EUR 6.92 million. Research and development expenses increased 49% to EUR 70.27 million, primarily due to clinical-trial costs, particularly SUPRAME.
2. Cash and milestones
Cash, cash equivalents and other financial assets totaled EUR 472.3 million at September 30, 2026, with cash reach projected into Q4 2028. SUPRAME topline data remain expected in the first half of 2027, followed by a BLA submission for anzu-cel in 2027.
